Principles and measures of medication risk management in the elderly

doi:10.19803/j.1672-8629.20220585

Abstract

Abstract: Objective To study the causes of medication risks in the elderly and recommend measures of management. Methods The risk factors for medication in the elderly were analyzed in terms of pharmacokinetics, pharmacodynamics, polypharmacy and poor medication compliance. The principles of risk management and control for the elderly were explained to ensure the medication safety. Results According to the principles of medication risk management for the elderly, a multidisciplinary geriatric work team was established for geriatric assessment. Active management and control strategies for drug risks among the elderly were formulated. Conclusion Active exploration of management and control measures against medication risks based on medication principles of the elderly is an effective solution to polypharmacy in the elderly.

Key words: elderly, polypharmacy, comprehensive assessment of the elderly, adverse drug reaction, risk management

CLC Number:

R994.11

ZHU Yuanchao, ZHANG Yatong, HU Xin. Principles and measures of medication risk management in the elderly[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.

References

[1] Ministry of Civil Affairs of China. Statistical Bulletin of Social Service Development in 2015[EB/OL]. (2016-07-11) [2022-09-26]. http://www.gov.cn/xinwen/2016-07/11/content_5090289.htm.
[2] National Bureau of Statistics of the People's Republic of China . Communiqué of the Seventh National Population Census (No. 5) [EB/OL]. (2021-05-11)(2022-11-30). http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html.
[3] FANG EF, SCHEIBY E-KNUDSEN M, JOHN HJ, et al. A research Agenda for aging in China the 21stcentury[J]. Ageing Res Rev, 2015, 24(PtB): 197-205.
[4] TINETTI ME, STUDENSKI SA.Comparative effectiveness research and patients with multiple chronic conditions[J]. N Engl J Med, 2011, 364(26): 2478-2481.
[5] World Health Organization. Medication safety in polypharmacy[EB/OL]. (2019-09-20)[2020-12-02]. https://apps.who.int/iris/bitstream/handle/10665/325454/WHO-UHC-SDS-2019.11-eng.pdf?sequence=1&isAllowed=y.
[6] CAO F,WANG YB,XUE WG.Clinical multi-centers report of chronic diseases among elderly inpatients in China[J]. Chin J Mult Organ Dis Elderly,2018, 17(11): 801-808.
[7] ALHAWASSI TM, KRASS I, BAJOREK BV, et al.A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting[J]. Clin Interv Aging, 2014, 9: 2079-2086.
[8] BUTLER JM, BEGG EJ.Free drug metabolic clearance in elderly people[J]. Clin Pharmacokinet, 2008, 47(5): 297-321.
[9] CERRETA F, EICHLER HG, RASI G.Drug policy for an aging population-the European Medicine Agency's geriatric medicines strategy[J]. NEngl J Med, 2012, 367(21): 1972-1974.
[10] CHARLESWORTH CJ, SMIT E, LEE D, et al.Polypharmacy among adults aged 65 years and older in the United States: 1988-2010[J]. J Gerontol A Biol Sci Med Sc, 2015, 70(8): 989-995.
[11] JOHNELL K, KLARIN L.The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600, 000 elderly patients from the Swedish Prescribed Drug Register[J]. Drug Saf, 2007, 30(10): 911-918.
[12] World Health Organization.Adherence to long-term therapies:evidence for action[EB/OL]. (2003-01-01)[2022-10-02]. http://www.who.int/chp/knowledge/publications/adherence_report/en.2003.
[13] LAI XX, HUO XP, AN QZ, et al.Survey and analysis of status quo of polypharmacy in elderly patients[J]. Chinese Nursing Research(护理研究), 2016, 30(19): 2374-2378.
[14] SINO CG, SIETZEMA M, EGBERTS TC, et al.Medication management capacity in relation to cognition and self-management skills older people on polypharmacy[J]. J Nutr Health Aging, 2014, 18(1): 44-49
[15] ZHU JL, JIANG J, HUO Y.Effect of mobile health on improving adherence in cardiovascular disease patients[J]. Adv Cardiovasc Dis(心血管病学进展), 2017, 38(6): 635-639.
[16] HANLON JT, SCHMADER KE, SAMSA GP, et al.A method for assessing drug therapy appropriateness[J]. J Clin Epidemiol,1992,45(10): 1045-1051.
[17] By the 2019 American Geriatrics Society Beers Criteria^® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria^® for Potentially Inappropriate Medication Use in Older Adults the 2019 American Geriatrics Society Beers Criteria^® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria^® for Potentially Inappropriate Medication Use in Older Adults[J]. J Am Geriatr Soc, 2019, 67(4): 674-694.
[18] O'MAHONY D, O'SULLIVAN D, BYRNE S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2[J]. Age Ageing, 2015, 44(2): 213-218.
[19] Rational Drug Use Branch of China Association of Geriatric Research. Criteria of Potentially Inappropriate Medication for Older Adults in China[J]. Adverse Drug Reac Journal(药物不良反应杂志), 2018, 20(1): 2-8.
[20] YIN LX, ZHANG LH.Special Population Medication Guidance Series: Medication Guidance for the Elderly (特殊人群用药指导丛书老年人用药指导) [M]. Beijing: People's Health Publishing House, 2012.
[21] GHOSH P, DEWANJI A.Effect of reporting bias in the analysis of spontaneous reporting data[J]. Pharm Stat, 2015, 14(1): 20-25.
[22] WADMAN M.Experts call for active surveillance of drug safety[J]. Nature, 2007, 446( 7134) : 358-359.
[23] WANG D.Active surveillance of adverse drug reaction and its development trend[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(10): 600-602.
[24] CHEN C, XU YJ, GUO DH, et al.Advances in the application of computer technology for drug safety monitoring in medical institutions[J]. China Pharm acy(中国药房), 2014, 25(5): 461-464.
[25] BIAN Y, FENG JJ, LIN L.Monitoring methods for adverse drug reactions[J]. J Chin Res Hosp(中国研究型医院), 2019, 6(3): 46-49.
[26] ZHAO ZN, JIN PF, ZHAO F, et al.Establishment and application of the active surveillance program for PD-1/PD-L1 inhibitor-associated lung injury[J]. Adverse Drug Reac Journal(药物不良反应杂志), 2022, 24(2): 61-66.
[27] ZHU YC, WU WB, SHEN J, et al.clinical characteristics and risk factors of cefoperazone sodium sulbactam sodium induced coagulation disorders[J]. Chin Pharm J(中国药学杂志), 2022, 57(9): 741-746.
[28] CAI Z, YANG W, HE Y, et al.Cefoperazone/sulbactam-induced abdominal wall hematoma and upper gastrointestinal bleeding: a case report and review of the literature[J]. Drug safety-case reports, 2016, 3(1):2.